Taltorvic (ridaforolimus) / Takeda, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 80 Diseases   2 Trials   2 Trials   151 News 


«123»
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Trial completion:  Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) -  Aug 30, 2017   
    P1,  N=24, Completed, 
    These findings support the safety and efficacy of RESs in patients who are representative of clinical practice. Active, not recruiting --> Completed
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Enrollment open:  BIONICS Israel Trial (clinicaltrials.gov) -  Nov 1, 2016   
    P=N/A,  N=60, Recruiting, 
    Trial primary completion date: Mar 2017 --> Sep 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    New trial:  BIONICS Israel Trial (clinicaltrials.gov) -  Jul 15, 2016   
    P=N/A,  N=60, Not yet recruiting, 
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Enrollment closed, Trial primary completion date:  Angiography Study of BioNIR Drug Eluting Stent System (NIREUS) (clinicaltrials.gov) -  Dec 23, 2015   
    P2,  N=300, Active, not recruiting, 
    No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2015
  • ||||||||||  Enrollment closed, Trial primary completion date:  BIONICS: Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (clinicaltrials.gov) -  Dec 4, 2015   
    P2,  N=1906, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Aug 2016
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Trial completion, Trial primary completion date, Metastases:  Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) -  Nov 10, 2015   
    P1,  N=16, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2014
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Trial primary completion date:  Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) -  Sep 24, 2015   
    P1,  N=24, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2014 Trial primary completion date: Dec 2015 --> Apr 2016
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Trial primary completion date, Metastases:  Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) -  Sep 8, 2015   
    P1,  N=16, Active, not recruiting, 
    Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Dec 2014 --> Dec 2016
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Trial primary completion date:  Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) -  Apr 23, 2015   
    P1,  N=24, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Dec 2015
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Trial primary completion date:  Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) -  Nov 18, 2014   
    P1,  N=24, Active, not recruiting, 
    Completed --> Active, not recruiting Trial primary completion date: Dec 2014 --> May 2015
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Enrollment closed:  Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) -  Jan 14, 2014   
    P1,  N=28, Active, not recruiting, 
    N=25 --> 48 Recruiting --> Active, not recruiting
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Erbitux (cetuximab) / Eli Lilly
    Trial termination, Metastases:  Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer (clinicaltrials.gov) -  Feb 21, 2013   
    P1,  N=12, Terminated, 
    Active, not recruiting --> Completed Recruiting --> Terminated; Determination to stop enrollment made due to funding